Although extensive and in-depth studies are needed to test the therapeutic benefits of targeting co-inhibitory pathways, current understanding indicates that enforcement of TIGIT axis may offer a new therapeutic approach for the treatment of autoimmune diseases. The gene discussed is TIGIT; the disease is autoimmune disease.